Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech

Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech

309536

Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech

Note: This story was updated Oct. 19, 2021, to better reflect the amount by which Nuravax’s vaccines can raise blood antibody levels. The nonprofit Institute for Molecular Medicine (IMM) has licensed its universal vaccine platform technology — called MultiTEP — to Nuravax, a biotech developing therapies for Alzheimer’s disease and other disorders of the central nervous system. MultiTEP is a vaccine platform that can generate very high levels of antibodies against toxic proteins that clump…

You must be logged in to read/download the full post.